Entero Therapeutics announced its entry into a binding letter of intent with Data Vault to exclusively license two technology product suites owned by Data Vault — QOLPOM and FotoDigm. Entero Therapeutics will work with Data Vault before and after the closing of the Proposed Transaction to secure funding for the customization of this clinical trial compliance software that includes a focus on the use of DigitalTwins and high-performance computing. In parallel, Entero Therapeutics plans to develop applications for its own near-term use with gastrointestinal clinical trials beginning with the planned Phase 3 trial for latiglutenase for the treatment of celiac disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTO:
- Entero Therapeutics receives noncompliance notification from Nasdaq
- Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
- Entero Therapeutics Welcomes Timothy Ramdeen to Board
- Entero Therapeutics Grapples with Financial Strain and Compliance Issues
- Entero Therapeutics Issues Shareholder Update Letter